ymfklier alloreactiviteit in niertransplantatie.
Recruiting
- Conditions
- kidney transplantation/ niertransplantatierejection/ rejectiealloreactivity/ alloreactiviteitlymph nodes/ lymfklieren
- Registration Number
- NL-OMON26812
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet the following criteria:
-Adult patients receiving a deceased or living kidney transplant in the Erasmus Medical Center Rotterdam, The Netherlands and:
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
-ABO-compatible HLA identical living-related transplant recipients.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -The primary objective for this study is to determine the prognostic characteristics for BPAR in the first 3 months after transplantation, as assessed in the lymphocyte composition of the lymph node in immunologically high-risk kidney transplantation. <br />
- Secondary Outcome Measures
Name Time Method Secondary objectives of the study:<br /><br>-to capture global composition of lymph node versus blood leukocyte subsets in renal insufficiency[20].<br /><br>-to compare the immunological ageing profile of T cells in the peripheral blood to the T cells derived from the lymph node.<br /><br>-to assess whether pre-transplant frequencies of lymph node derived TFH, T and B cells predict BPAR.<br /><br>-to assess differences in lymphocyte composition of lymph nodes in alemtuzumab treated versus untreated patients both in single cell suspension and within the tissue [21, 22]. (ABO-incompatible kidney transplant recipients receive alemtuzumab induction therapy three weeks before transplantation).<br /><br>This study will result in a set of defined markers that will identify patients at risk to develop rejection. <br>